[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fRK5fmycubU4wNkR2R6A20a_NwqAqOwghzZbtI_qUCzA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":64,"rows":71},"Henry M. Jackson Foundation for the Advancement of Military Medicine",[4],83,false,20,3,72035,17,58,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"HIV Infections",10,{"name":18,"count":19},"Traumatic Brain Injury",6,{"name":21,"count":19},"Influenza",{"name":23,"count":24},"Mild Traumatic Brain Injury",4,{"name":26,"count":24},"Critical Illness",{"name":28,"count":24},"Suicide, Attempted",{"name":30,"count":24},"Obesity",{"name":32,"count":9},"Pregnancy",[34,39,44,49,54,59],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03734237","A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD","2022-07-07","Egg based influenza vaccines",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05677282","Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct","2025-09","Rifaximin 550 MG",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05049057","Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI","2026-05-19","Erenumab 140 Mg\u002FmL Subcutaneous Solution",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06854393","Lacripep for Corneal Wound Healing Study","2027-06","0.00025% Lacripep ophthalmic solution and Placebo",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06484335","RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV","2027-08-01","VRC07-523LS",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07287137","Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study","2027-09","Pfizer-BioNTech mRNA COVID-19 vaccine",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,100,118,136,162,180,198,226,244,266,287,331,353,375,397,415,433,451,480,505,531,549,574,592,618,645,663,688,715,733,751,775,793,811,829,847,871,897,915,933,959,985,1011,1029,1054,1072,1096,1120],{"intervention":38,"totalTrials":73,"cells":74},1,{"EARLY_PHASE1":75,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":98},{"trials":76,"activeCount":77},[],0,{"trials":79,"activeCount":77},[],{"trials":81,"activeCount":77},[],{"trials":83,"activeCount":77},[],{"trials":85,"activeCount":73,"soonestReadout":37},[86],{"nctId":35,"briefTitle":36,"status":87,"phases":88,"primaryCompletion":37,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":95},"ACTIVE_NOT_RECRUITING",[69],"2026-06-30","2018-11-06",15448,[21,93,94],"Influenza-like Illness","Influenza Vaccines",[38,96,97],"Recombinant influenza vaccines","Cell-culture based influenza vaccines",{"trials":99,"activeCount":77},[],{"intervention":96,"totalTrials":73,"cells":101},{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":116},{"trials":103,"activeCount":77},[],{"trials":105,"activeCount":77},[],{"trials":107,"activeCount":77},[],{"trials":109,"activeCount":77},[],{"trials":111,"activeCount":73,"soonestReadout":37},[112],{"nctId":35,"briefTitle":36,"status":87,"phases":113,"primaryCompletion":37,"completion":89,"start":90,"enrollment":91,"conditions":114,"interventions":115},[69],[21,93,94],[38,96,97],{"trials":117,"activeCount":77},[],{"intervention":97,"totalTrials":73,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":128,"NA":134},{"trials":121,"activeCount":77},[],{"trials":123,"activeCount":77},[],{"trials":125,"activeCount":77},[],{"trials":127,"activeCount":77},[],{"trials":129,"activeCount":73,"soonestReadout":37},[130],{"nctId":35,"briefTitle":36,"status":87,"phases":131,"primaryCompletion":37,"completion":89,"start":90,"enrollment":91,"conditions":132,"interventions":133},[69],[21,93,94],[38,96,97],{"trials":135,"activeCount":77},[],{"intervention":43,"totalTrials":73,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":160},{"trials":139,"activeCount":77},[],{"trials":141,"activeCount":77},[],{"trials":143,"activeCount":77},[],{"trials":145,"activeCount":77},[],{"trials":147,"activeCount":73,"soonestReadout":42},[148],{"nctId":40,"briefTitle":41,"status":149,"phases":150,"primaryCompletion":42,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":157},"RECRUITING",[69],"2025-12","2022-10-28",150,[155,156],"Diarrhoea;Acute","Diarrhea Travelers",[43,158,159],"Azithromycin 500 MG","Loperamide",{"trials":161,"activeCount":77},[],{"intervention":158,"totalTrials":73,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":178},{"trials":165,"activeCount":77},[],{"trials":167,"activeCount":77},[],{"trials":169,"activeCount":77},[],{"trials":171,"activeCount":77},[],{"trials":173,"activeCount":73,"soonestReadout":42},[174],{"nctId":40,"briefTitle":41,"status":149,"phases":175,"primaryCompletion":42,"completion":151,"start":152,"enrollment":153,"conditions":176,"interventions":177},[69],[155,156],[43,158,159],{"trials":179,"activeCount":77},[],{"intervention":159,"totalTrials":73,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":196},{"trials":183,"activeCount":77},[],{"trials":185,"activeCount":77},[],{"trials":187,"activeCount":77},[],{"trials":189,"activeCount":77},[],{"trials":191,"activeCount":73,"soonestReadout":42},[192],{"nctId":40,"briefTitle":41,"status":149,"phases":193,"primaryCompletion":42,"completion":151,"start":152,"enrollment":153,"conditions":194,"interventions":195},[69],[155,156],[43,158,159],{"trials":197,"activeCount":77},[],{"intervention":63,"totalTrials":73,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":224},{"trials":201,"activeCount":77},[],{"trials":203,"activeCount":77},[],{"trials":205,"activeCount":77},[],{"trials":207,"activeCount":77},[],{"trials":209,"activeCount":73,"soonestReadout":62},[210],{"nctId":60,"briefTitle":61,"status":87,"phases":211,"primaryCompletion":62,"completion":62,"start":212,"enrollment":213,"conditions":214,"interventions":222},[69],"2025-11-12",54,[215,216,217,21,218,219,220,221],"COVID -19","COVID - 19","COVID 19","Respiratory Virus","Respiratory Viruses","Respiratory Virus Infection","Respiratory Virus Infections",[63,223],"Novavax recombinant protein vaccine",{"trials":225,"activeCount":77},[],{"intervention":223,"totalTrials":73,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":242},{"trials":229,"activeCount":77},[],{"trials":231,"activeCount":77},[],{"trials":233,"activeCount":77},[],{"trials":235,"activeCount":77},[],{"trials":237,"activeCount":73,"soonestReadout":62},[238],{"nctId":60,"briefTitle":61,"status":87,"phases":239,"primaryCompletion":62,"completion":62,"start":212,"enrollment":213,"conditions":240,"interventions":241},[69],[215,216,217,21,218,219,220,221],[63,223],{"trials":243,"activeCount":77},[],{"intervention":48,"totalTrials":73,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":260,"PHASE4":262,"NA":264},{"trials":247,"activeCount":77},[],{"trials":249,"activeCount":77},[],{"trials":251,"activeCount":73,"soonestReadout":47},[252],{"nctId":45,"briefTitle":46,"status":149,"phases":253,"primaryCompletion":47,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":259},[67],"2027-05-19","2022-07-19",404,[258,23],"Posttraumatic Headache",[48],{"trials":261,"activeCount":77},[],{"trials":263,"activeCount":77},[],{"trials":265,"activeCount":77},[],{"intervention":53,"totalTrials":73,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":281,"PHASE4":283,"NA":285},{"trials":269,"activeCount":77},[],{"trials":271,"activeCount":77},[],{"trials":273,"activeCount":73,"soonestReadout":52},[274],{"nctId":50,"briefTitle":51,"status":149,"phases":275,"primaryCompletion":52,"completion":62,"start":276,"enrollment":277,"conditions":278,"interventions":280},[67],"2025-05-23",88,[279],"Corneal Epithelial Wound Healing",[53],{"trials":282,"activeCount":77},[],{"trials":284,"activeCount":77},[],{"trials":286,"activeCount":77},[],{"intervention":58,"totalTrials":288,"cells":289},2,{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":323,"PHASE3":325,"PHASE4":327,"NA":329},{"trials":291,"activeCount":77},[],{"trials":293,"activeCount":73,"soonestReadout":57},[294,311],{"nctId":295,"briefTitle":296,"status":297,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":77,"conditions":301,"interventions":303},"NCT05769569","Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission","WITHDRAWN",[66],"2025-07-01","2023-09-01",[302],"HIV-1-infection",[58,304,305,306,307,308,309,310],"PGDM1400LS","N-803","Ad26.Mos4.HIV","MVA-BN-HIV","A244d11 gp120","ALFQ","Antiretroviral Therapy",{"nctId":55,"briefTitle":56,"status":149,"phases":312,"primaryCompletion":57,"completion":57,"start":313,"enrollment":314,"conditions":315,"interventions":319},[66],"2025-03-27",48,[15,316,317,318],"PLWH","ART","Acute HIV Infection",[58,304,320,321,322,308,309],"ChAdOx1.tHIVconsv1","ChAdOx1.HIVconsv62","MVA.tHIVconsv4",{"trials":324,"activeCount":77},[],{"trials":326,"activeCount":77},[],{"trials":328,"activeCount":77},[],{"trials":330,"activeCount":77},[],{"intervention":304,"totalTrials":288,"cells":332},{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":351},{"trials":334,"activeCount":77},[],{"trials":336,"activeCount":73,"soonestReadout":57},[337,341],{"nctId":295,"briefTitle":296,"status":297,"phases":338,"primaryCompletion":299,"completion":299,"start":300,"enrollment":77,"conditions":339,"interventions":340},[66],[302],[58,304,305,306,307,308,309,310],{"nctId":55,"briefTitle":56,"status":149,"phases":342,"primaryCompletion":57,"completion":57,"start":313,"enrollment":314,"conditions":343,"interventions":344},[66],[15,316,317,318],[58,304,320,321,322,308,309],{"trials":346,"activeCount":77},[],{"trials":348,"activeCount":77},[],{"trials":350,"activeCount":77},[],{"trials":352,"activeCount":77},[],{"intervention":308,"totalTrials":288,"cells":354},{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":373},{"trials":356,"activeCount":77},[],{"trials":358,"activeCount":73,"soonestReadout":57},[359,363],{"nctId":295,"briefTitle":296,"status":297,"phases":360,"primaryCompletion":299,"completion":299,"start":300,"enrollment":77,"conditions":361,"interventions":362},[66],[302],[58,304,305,306,307,308,309,310],{"nctId":55,"briefTitle":56,"status":149,"phases":364,"primaryCompletion":57,"completion":57,"start":313,"enrollment":314,"conditions":365,"interventions":366},[66],[15,316,317,318],[58,304,320,321,322,308,309],{"trials":368,"activeCount":77},[],{"trials":370,"activeCount":77},[],{"trials":372,"activeCount":77},[],{"trials":374,"activeCount":77},[],{"intervention":309,"totalTrials":288,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":389,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":378,"activeCount":77},[],{"trials":380,"activeCount":73,"soonestReadout":57},[381,385],{"nctId":295,"briefTitle":296,"status":297,"phases":382,"primaryCompletion":299,"completion":299,"start":300,"enrollment":77,"conditions":383,"interventions":384},[66],[302],[58,304,305,306,307,308,309,310],{"nctId":55,"briefTitle":56,"status":149,"phases":386,"primaryCompletion":57,"completion":57,"start":313,"enrollment":314,"conditions":387,"interventions":388},[66],[15,316,317,318],[58,304,320,321,322,308,309],{"trials":390,"activeCount":77},[],{"trials":392,"activeCount":77},[],{"trials":394,"activeCount":77},[],{"trials":396,"activeCount":77},[],{"intervention":320,"totalTrials":73,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":400,"activeCount":77},[],{"trials":402,"activeCount":73,"soonestReadout":57},[403],{"nctId":55,"briefTitle":56,"status":149,"phases":404,"primaryCompletion":57,"completion":57,"start":313,"enrollment":314,"conditions":405,"interventions":406},[66],[15,316,317,318],[58,304,320,321,322,308,309],{"trials":408,"activeCount":77},[],{"trials":410,"activeCount":77},[],{"trials":412,"activeCount":77},[],{"trials":414,"activeCount":77},[],{"intervention":321,"totalTrials":73,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":418,"activeCount":77},[],{"trials":420,"activeCount":73,"soonestReadout":57},[421],{"nctId":55,"briefTitle":56,"status":149,"phases":422,"primaryCompletion":57,"completion":57,"start":313,"enrollment":314,"conditions":423,"interventions":424},[66],[15,316,317,318],[58,304,320,321,322,308,309],{"trials":426,"activeCount":77},[],{"trials":428,"activeCount":77},[],{"trials":430,"activeCount":77},[],{"trials":432,"activeCount":77},[],{"intervention":322,"totalTrials":73,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":443,"PHASE3":445,"PHASE4":447,"NA":449},{"trials":436,"activeCount":77},[],{"trials":438,"activeCount":73,"soonestReadout":57},[439],{"nctId":55,"briefTitle":56,"status":149,"phases":440,"primaryCompletion":57,"completion":57,"start":313,"enrollment":314,"conditions":441,"interventions":442},[66],[15,316,317,318],[58,304,320,321,322,308,309],{"trials":444,"activeCount":77},[],{"trials":446,"activeCount":77},[],{"trials":448,"activeCount":77},[],{"trials":450,"activeCount":77},[],{"intervention":452,"totalTrials":73,"cells":453},"Ketamine with propofol",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":478},{"trials":455,"activeCount":77},[],{"trials":457,"activeCount":77},[],{"trials":459,"activeCount":77},[],{"trials":461,"activeCount":77},[],{"trials":463,"activeCount":77},[464],{"nctId":465,"briefTitle":466,"status":467,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":477},"NCT06429657","Ketamine for Sedation in Severe Traumatic Brain Injury","SUSPENDED",[69],"2027-01-01","2027-06-30","2024-09-23",50,[474,475,476],"Severe Traumatic Brain Injury","Intracranial Hypertension","Intracranial Hemorrhage, Hypertensive",[452],{"trials":479,"activeCount":77},[],{"intervention":481,"totalTrials":73,"cells":482},"FluMist",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":503},{"trials":484,"activeCount":77},[],{"trials":486,"activeCount":77},[],{"trials":488,"activeCount":77},[],{"trials":490,"activeCount":77},[],{"trials":492,"activeCount":77},[493],{"nctId":494,"briefTitle":495,"status":496,"phases":497,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":502},"NCT01933048","Self-Administered Nasal Influenza Feasibility Study","COMPLETED",[69],"2013-10","2012-09",1077,[21],[481],{"trials":504,"activeCount":77},[],{"intervention":506,"totalTrials":73,"cells":507},"pneumococcal conjugate vaccine",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":527,"NA":529},{"trials":509,"activeCount":77},[],{"trials":511,"activeCount":77},[],{"trials":513,"activeCount":77},[],{"trials":515,"activeCount":77},[516],{"nctId":517,"briefTitle":518,"status":496,"phases":519,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT00622843","Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting",[68],"2013-07","2002-12",275,[15,524],"Streptococcus Pneumoniae",[506,526],"pneumococcal polysaccharide vaccine",{"trials":528,"activeCount":77},[],{"trials":530,"activeCount":77},[],{"intervention":526,"totalTrials":73,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":545,"NA":547},{"trials":534,"activeCount":77},[],{"trials":536,"activeCount":77},[],{"trials":538,"activeCount":77},[],{"trials":540,"activeCount":77},[541],{"nctId":517,"briefTitle":518,"status":496,"phases":542,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":543,"interventions":544},[68],[15,524],[506,526],{"trials":546,"activeCount":77},[],{"trials":548,"activeCount":77},[],{"intervention":550,"totalTrials":73,"cells":551},"Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine",{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":570,"NA":572},{"trials":553,"activeCount":77},[],{"trials":555,"activeCount":77},[],{"trials":557,"activeCount":77},[],{"trials":559,"activeCount":77},[560],{"nctId":561,"briefTitle":562,"status":297,"phases":563,"primaryCompletion":564,"completion":564,"start":565,"enrollment":77,"conditions":566,"interventions":568},"NCT04632537","BCG Vaccination to Prevent COVID-19",[68],"2021-03-23","2020-12-07",[567],"COVID-19",[550,569],"Preservative-free saline",{"trials":571,"activeCount":77},[],{"trials":573,"activeCount":77},[],{"intervention":569,"totalTrials":73,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":588,"NA":590},{"trials":577,"activeCount":77},[],{"trials":579,"activeCount":77},[],{"trials":581,"activeCount":77},[],{"trials":583,"activeCount":77},[584],{"nctId":561,"briefTitle":562,"status":297,"phases":585,"primaryCompletion":564,"completion":564,"start":565,"enrollment":77,"conditions":586,"interventions":587},[68],[567],[550,569],{"trials":589,"activeCount":77},[],{"trials":591,"activeCount":77},[],{"intervention":593,"totalTrials":73,"cells":594},"BCG (Tokyo 172) vaccine",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":614,"NA":616},{"trials":596,"activeCount":77},[],{"trials":598,"activeCount":77},[],{"trials":600,"activeCount":77},[],{"trials":602,"activeCount":77},[603],{"nctId":604,"briefTitle":605,"status":606,"phases":607,"primaryCompletion":608,"completion":608,"start":609,"enrollment":610,"conditions":611,"interventions":613},"NCT04453293","Immunization With BCG Vaccine to Prevent Tuberculosis Infection","TERMINATED",[68],"2026-01-16","2021-12-01",16,[612],"Tuberculosis Infection",[593],{"trials":615,"activeCount":77},[],{"trials":617,"activeCount":77},[],{"intervention":619,"totalTrials":73,"cells":620},"imatinib mesylate by mouth",{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":622,"activeCount":77},[],{"trials":624,"activeCount":77},[],{"trials":626,"activeCount":77},[627],{"nctId":628,"briefTitle":629,"status":496,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":637},"NCT00928642","Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer",[67],"2010-11","2009-06",8,[635,636],"Ovarian Cancer","Primary Peritoneal Cancer",[619,638],"Gemcitabine Intravenous",{"trials":640,"activeCount":77},[],{"trials":642,"activeCount":77},[],{"trials":644,"activeCount":77},[],{"intervention":638,"totalTrials":73,"cells":646},{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":648,"activeCount":77},[],{"trials":650,"activeCount":77},[],{"trials":652,"activeCount":77},[653],{"nctId":628,"briefTitle":629,"status":496,"phases":654,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":655,"interventions":656},[67],[635,636],[619,638],{"trials":658,"activeCount":77},[],{"trials":660,"activeCount":77},[],{"trials":662,"activeCount":77},[],{"intervention":664,"totalTrials":73,"cells":665},"Upamostat",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":667,"activeCount":77},[],{"trials":669,"activeCount":77},[],{"trials":671,"activeCount":77},[672],{"nctId":673,"briefTitle":674,"status":496,"phases":675,"primaryCompletion":676,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":681},"NCT05954286","PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19",[67],"2025-04-24","2024-01-29",92,[680],"SARS-CoV-2",[664],{"trials":683,"activeCount":77},[],{"trials":685,"activeCount":77},[],{"trials":687,"activeCount":77},[],{"intervention":689,"totalTrials":73,"cells":690},"Monovalent rAT",{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":709,"PHASE4":711,"NA":713},{"trials":692,"activeCount":77},[],{"trials":694,"activeCount":77},[],{"trials":696,"activeCount":77},[697],{"nctId":698,"briefTitle":699,"status":496,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":706},"NCT01011335","Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial",[66,67],"2011-03","2009-11",176,[705],"Staphylococcus Aureus",[689,707,708],"Monovalent rLukS-PV","Bivalent rLukS-PV \u002F rAT",{"trials":710,"activeCount":77},[],{"trials":712,"activeCount":77},[],{"trials":714,"activeCount":77},[],{"intervention":707,"totalTrials":73,"cells":716},{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":718,"activeCount":77},[],{"trials":720,"activeCount":77},[],{"trials":722,"activeCount":77},[723],{"nctId":698,"briefTitle":699,"status":496,"phases":724,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":725,"interventions":726},[66,67],[705],[689,707,708],{"trials":728,"activeCount":77},[],{"trials":730,"activeCount":77},[],{"trials":732,"activeCount":77},[],{"intervention":708,"totalTrials":73,"cells":734},{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":745,"PHASE4":747,"NA":749},{"trials":736,"activeCount":77},[],{"trials":738,"activeCount":77},[],{"trials":740,"activeCount":77},[741],{"nctId":698,"briefTitle":699,"status":496,"phases":742,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":743,"interventions":744},[66,67],[705],[689,707,708],{"trials":746,"activeCount":77},[],{"trials":748,"activeCount":77},[],{"trials":750,"activeCount":77},[],{"intervention":752,"totalTrials":73,"cells":753},"Procellera",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":755,"activeCount":77},[],{"trials":757,"activeCount":77},[],{"trials":759,"activeCount":77},[760],{"nctId":761,"briefTitle":762,"status":606,"phases":763,"primaryCompletion":764,"completion":764,"start":765,"enrollment":288,"conditions":766,"interventions":768},"NCT01784887","Clinical and Mechanistic Demonstration of a Bioelectric Dressing System for Non-healing Wound Management: A Phase II Trial",[66,67],"2015-03","2013-01",[767],"Non-healing Soft Tissue Wounds",[752],{"trials":770,"activeCount":77},[],{"trials":772,"activeCount":77},[],{"trials":774,"activeCount":77},[],{"intervention":305,"totalTrials":73,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":778,"activeCount":77},[],{"trials":780,"activeCount":77},[781],{"nctId":295,"briefTitle":296,"status":297,"phases":782,"primaryCompletion":299,"completion":299,"start":300,"enrollment":77,"conditions":783,"interventions":784},[66],[302],[58,304,305,306,307,308,309,310],{"trials":786,"activeCount":77},[],{"trials":788,"activeCount":77},[],{"trials":790,"activeCount":77},[],{"trials":792,"activeCount":77},[],{"intervention":306,"totalTrials":73,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":803,"PHASE3":805,"PHASE4":807,"NA":809},{"trials":796,"activeCount":77},[],{"trials":798,"activeCount":77},[799],{"nctId":295,"briefTitle":296,"status":297,"phases":800,"primaryCompletion":299,"completion":299,"start":300,"enrollment":77,"conditions":801,"interventions":802},[66],[302],[58,304,305,306,307,308,309,310],{"trials":804,"activeCount":77},[],{"trials":806,"activeCount":77},[],{"trials":808,"activeCount":77},[],{"trials":810,"activeCount":77},[],{"intervention":307,"totalTrials":73,"cells":812},{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":821,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":814,"activeCount":77},[],{"trials":816,"activeCount":77},[817],{"nctId":295,"briefTitle":296,"status":297,"phases":818,"primaryCompletion":299,"completion":299,"start":300,"enrollment":77,"conditions":819,"interventions":820},[66],[302],[58,304,305,306,307,308,309,310],{"trials":822,"activeCount":77},[],{"trials":824,"activeCount":77},[],{"trials":826,"activeCount":77},[],{"trials":828,"activeCount":77},[],{"intervention":310,"totalTrials":73,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":839,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":832,"activeCount":77},[],{"trials":834,"activeCount":77},[835],{"nctId":295,"briefTitle":296,"status":297,"phases":836,"primaryCompletion":299,"completion":299,"start":300,"enrollment":77,"conditions":837,"interventions":838},[66],[302],[58,304,305,306,307,308,309,310],{"trials":840,"activeCount":77},[],{"trials":842,"activeCount":77},[],{"trials":844,"activeCount":77},[],{"trials":846,"activeCount":77},[],{"intervention":848,"totalTrials":73,"cells":849},"Botulinum Type B",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":851,"activeCount":77},[],{"trials":853,"activeCount":77},[854],{"nctId":855,"briefTitle":856,"status":496,"phases":857,"primaryCompletion":858,"completion":858,"start":859,"enrollment":8,"conditions":860,"interventions":862},"NCT01671800","Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating",[66],"2012-12","2008-09",[861],"Hyperhidrosis",[848],{"trials":864,"activeCount":77},[],{"trials":866,"activeCount":77},[],{"trials":868,"activeCount":77},[],{"trials":870,"activeCount":77},[],{"intervention":872,"totalTrials":73,"cells":873},"HIVIS DNA\u002FMVA-CMDR",{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":889,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":875,"activeCount":77},[],{"trials":877,"activeCount":77},[878],{"nctId":879,"briefTitle":880,"status":496,"phases":881,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":886},"NCT04301154","Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth",[66],"2023-10-16","2022-02-18",25,[15],[872,887,888],"HIVIS DNA + Cervarix and MVA-CMDR","Cervarix",{"trials":890,"activeCount":77},[],{"trials":892,"activeCount":77},[],{"trials":894,"activeCount":77},[],{"trials":896,"activeCount":77},[],{"intervention":887,"totalTrials":73,"cells":898},{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":907,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":900,"activeCount":77},[],{"trials":902,"activeCount":77},[903],{"nctId":879,"briefTitle":880,"status":496,"phases":904,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":905,"interventions":906},[66],[15],[872,887,888],{"trials":908,"activeCount":77},[],{"trials":910,"activeCount":77},[],{"trials":912,"activeCount":77},[],{"trials":914,"activeCount":77},[],{"intervention":888,"totalTrials":73,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":925,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":918,"activeCount":77},[],{"trials":920,"activeCount":77},[921],{"nctId":879,"briefTitle":880,"status":496,"phases":922,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":923,"interventions":924},[66],[15],[872,887,888],{"trials":926,"activeCount":77},[],{"trials":928,"activeCount":77},[],{"trials":930,"activeCount":77},[],{"trials":932,"activeCount":77},[],{"intervention":934,"totalTrials":73,"cells":935},"Chlorhexidine gluconate",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":944,"NA":946},{"trials":937,"activeCount":77},[],{"trials":939,"activeCount":77},[],{"trials":941,"activeCount":77},[],{"trials":943,"activeCount":77},[],{"trials":945,"activeCount":77},[],{"trials":947,"activeCount":77},[948],{"nctId":949,"briefTitle":950,"status":496,"phases":951,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":958},"NCT01105767","Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees",[70],"2012-01","2010-05",30209,[705,956,957],"MRSA Skin Infections","Staphylococcal Skin Infections",[934],{"intervention":960,"totalTrials":73,"cells":961},"Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%",{"EARLY_PHASE1":962,"PHASE1":964,"PHASE2":966,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":963,"activeCount":77},[],{"trials":965,"activeCount":77},[],{"trials":967,"activeCount":77},[],{"trials":969,"activeCount":77},[],{"trials":971,"activeCount":77},[],{"trials":973,"activeCount":77},[974],{"nctId":975,"briefTitle":976,"status":496,"phases":977,"primaryCompletion":978,"completion":979,"start":980,"enrollment":981,"conditions":982,"interventions":984},"NCT00631566","Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons",[70],"2017-05","2017-10","2007-05",550,[15,983],"Staphylococcal Infections",[960],{"intervention":986,"totalTrials":73,"cells":987},"BST",{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":994,"PHASE4":996,"NA":998},{"trials":989,"activeCount":77},[],{"trials":991,"activeCount":77},[],{"trials":993,"activeCount":77},[],{"trials":995,"activeCount":77},[],{"trials":997,"activeCount":77},[],{"trials":999,"activeCount":77},[1000],{"nctId":1001,"briefTitle":1002,"status":496,"phases":1003,"primaryCompletion":632,"completion":1004,"start":1005,"enrollment":1006,"conditions":1007,"interventions":1009},"NCT00804713","Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits",[70],"2022-08","2009-03",2017,[1008],"Latent Tuberculosis Infection",[986,1010],"TST",{"intervention":1010,"totalTrials":73,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1023},{"trials":1014,"activeCount":77},[],{"trials":1016,"activeCount":77},[],{"trials":1018,"activeCount":77},[],{"trials":1020,"activeCount":77},[],{"trials":1022,"activeCount":77},[],{"trials":1024,"activeCount":77},[1025],{"nctId":1001,"briefTitle":1002,"status":496,"phases":1026,"primaryCompletion":632,"completion":1004,"start":1005,"enrollment":1006,"conditions":1027,"interventions":1028},[70],[1008],[986,1010],{"intervention":1030,"totalTrials":73,"cells":1031},"2% chlorhexidine gluconate (CHG) impregnated cloths",{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1033,"activeCount":77},[],{"trials":1035,"activeCount":77},[],{"trials":1037,"activeCount":77},[],{"trials":1039,"activeCount":77},[],{"trials":1041,"activeCount":77},[],{"trials":1043,"activeCount":77},[1044],{"nctId":1045,"briefTitle":1046,"status":496,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":980,"enrollment":1049,"conditions":1050,"interventions":1052},"NCT00475930","Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates",[70],"2007-11",1563,[705,1051,957],"Community-acquired Infections",[1030,1053],"Comfort Bath cloths",{"intervention":1053,"totalTrials":73,"cells":1055},{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1057,"activeCount":77},[],{"trials":1059,"activeCount":77},[],{"trials":1061,"activeCount":77},[],{"trials":1063,"activeCount":77},[],{"trials":1065,"activeCount":77},[],{"trials":1067,"activeCount":77},[1068],{"nctId":1045,"briefTitle":1046,"status":496,"phases":1069,"primaryCompletion":1048,"completion":1048,"start":980,"enrollment":1049,"conditions":1070,"interventions":1071},[70],[705,1051,957],[1030,1053],{"intervention":1073,"totalTrials":73,"cells":1074},"Genvoya 150Mg-150Mg-200Mg-10Mg",{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1076,"activeCount":77},[],{"trials":1078,"activeCount":77},[],{"trials":1080,"activeCount":77},[],{"trials":1082,"activeCount":77},[],{"trials":1084,"activeCount":77},[],{"trials":1086,"activeCount":77},[1087],{"nctId":1088,"briefTitle":1089,"status":297,"phases":1090,"primaryCompletion":1091,"completion":1092,"start":1093,"enrollment":77,"conditions":1094,"interventions":1095},"NCT03877536","Antiretroviral Therapy for Acute HIV Infection",[70],"2023-09-14","2025-09-14","2019-03-17",[15],[1073],{"intervention":1097,"totalTrials":73,"cells":1098},"Rizatriptan",{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1105,"PHASE4":1107,"NA":1109},{"trials":1100,"activeCount":77},[],{"trials":1102,"activeCount":77},[],{"trials":1104,"activeCount":77},[],{"trials":1106,"activeCount":77},[],{"trials":1108,"activeCount":77},[],{"trials":1110,"activeCount":77},[1111],{"nctId":1112,"briefTitle":1113,"status":297,"phases":1114,"primaryCompletion":1115,"completion":1115,"start":1116,"enrollment":77,"conditions":1117,"interventions":1119},"NCT01306266","Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops",[70],"2011-08","2011-02",[1118],"Chronic Post-traumatic Headache",[1097],{"intervention":1121,"totalTrials":73,"cells":1122},"Rifaximin",{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1129,"PHASE4":1131,"NA":1133},{"trials":1124,"activeCount":77},[],{"trials":1126,"activeCount":77},[],{"trials":1128,"activeCount":77},[],{"trials":1130,"activeCount":77},[],{"trials":1132,"activeCount":77},[],{"trials":1134,"activeCount":77},[1135],{"nctId":1136,"briefTitle":1137,"status":496,"phases":1138,"primaryCompletion":1139,"completion":1140,"start":1141,"enrollment":1142,"conditions":1143,"interventions":1147},"NCT02498301","Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD",[70],"2019-07","2019-12-31","2015-11-10",449,[1144,1145,1146],"Travelers' Diarrhea","Functional Bowel Disorders","Reactive Arthritis",[1121]]